ULTRAGENYX PHARMACEUTICAL INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $3.78 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2019-11-06
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2019-09-30 was $7.21M, a 161.95% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2019-06-30 was $9.50M, a 71.32% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2019-03-31 was -$12.93M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2018-12-31 was $3.28M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2018 was -$1.01M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2017 was -$4.63M, a 114.38% decline from fiscal 2016.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2016 was $32.19M, a 93.10% increase from fiscal 2015.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2015 was $16.67M, a 378.89% increase from fiscal 2014.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 47 month |
|---|---|---|---|---|---|
| 2019-09-30 | $7.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $16.71M derived: sum of 2 quarters · filed 2019-11-06 | $3.78M 10-Q · filed 2019-11-06 | $7.05M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2019-06-30 | $9.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | -$3.43M 10-Q · filed 2019-08-02 | -$156.00K derived: sum of 3 quarters · filed 2019-08-02 | $2.60M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2019-03-31 | -$12.93M 10-Q · filed 2019-05-07 | -$9.65M derived: sum of 2 quarters · filed 2019-05-07 | -$6.90M derived: sum of 3 quarters · filed 2019-11-06 | -$1.36M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2018-12-31 | $3.28M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $6.03M derived: sum of 2 quarters · filed 2019-11-06 | $11.57M derived: sum of 3 quarters · filed 2019-11-06 | -$1.01M 10-K · filed 2019-02-20 | |
| 2018-09-30 | $2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $8.30M derived: sum of 2 quarters · filed 2019-11-06 | -$4.29M 10-Q · filed 2019-11-06 | -$7.37M derived: sum of 4 quarters · filed 2019-11-06 | |
| 2018-06-30 | $5.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | -$7.04M 10-Q · filed 2019-08-02 | -$10.12M derived: sum of 3 quarters · filed 2019-08-02 | -$5.94M derived: sum of 4 quarters · filed 2019-08-02 | |
| 2018-03-31 | -$12.58M 10-Q · filed 2019-05-07 | -$15.66M derived: sum of 2 quarters · filed 2019-05-07 | -$11.49M derived: sum of 3 quarters · filed 2019-05-07 | -$4.74M derived: sum of 4 quarters · filed 2019-05-07 | |
| 2017-12-31 | -$3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $1.10M derived: sum of 2 quarters · filed 2019-02-20 | $7.84M derived: sum of 3 quarters · filed 2019-02-20 | -$4.63M 10-K · filed 2019-02-20 | |
| 2017-09-30 | $4.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $10.92M derived: sum of 2 quarters · filed 2018-11-06 | -$1.55M 10-Q · filed 2018-11-06 | $8.05M derived: sum of 4 quarters · filed 2019-02-20 | |
| 2017-06-30 | $6.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | -$5.72M 10-Q · filed 2018-08-03 | $3.88M derived: sum of 3 quarters · filed 2019-02-20 | $24.28M derived: sum of 4 quarters · filed 2019-02-20 | |
| 2017-03-31 | -$12.47M 10-Q · filed 2018-05-08 | -$2.87M derived: sum of 2 quarters · filed 2019-02-20 | $17.54M derived: sum of 3 quarters · filed 2019-02-20 | $21.59M derived: sum of 4 quarters · filed 2019-02-20 | |
| 2016-12-31 | $9.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $30.01M derived: sum of 2 quarters · filed 2019-02-20 | $34.06M derived: sum of 3 quarters · filed 2019-02-20 | $32.19M 10-K · filed 2019-02-20 | |
| 2016-09-30 | $20.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $24.46M derived: sum of 2 quarters · filed 2017-11-03 | $22.59M 10-Q · filed 2017-11-03 | $27.49M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-06-30 | $4.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $2.18M 10-Q · filed 2017-07-28 | $7.09M derived: sum of 3 quarters · filed 2018-02-21 | $14.07M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2016-03-31 | -$1.87M 10-Q · filed 2017-05-05 | $3.04M derived: sum of 2 quarters · filed 2018-02-21 | $10.02M derived: sum of 3 quarters · filed 2018-02-21 | $14.14M derived: sum of 4 quarters · filed 2018-02-21 | |
| 2015-12-31 | $4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $11.89M derived: sum of 2 quarters · filed 2018-02-21 | $16.01M derived: sum of 3 quarters · filed 2018-02-21 | $16.67M 10-K · filed 2018-02-21 | |
| 2015-09-30 | $6.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | $11.10M derived: sum of 2 quarters · filed 2016-11-08 | $11.77M 10-Q · filed 2016-11-08 | $12.53M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-06-30 | $4.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $4.78M 10-Q · filed 2016-08-09 | $5.54M derived: sum of 3 quarters · filed 2017-02-17 | $7.03M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-03-31 | $664.00K 10-Q · filed 2016-05-10 | $1.43M derived: sum of 2 quarters · filed 2017-02-17 | $2.92M derived: sum of 3 quarters · filed 2017-02-17 | $5.33M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2014-12-31 | $762.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $2.25M derived: sum of 2 quarters · filed 2017-02-17 | $4.67M derived: sum of 3 quarters · filed 2017-02-17 | $3.48M 10-K · filed 2017-02-17 | |
| 2014-09-30 | $1.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $3.90M derived: sum of 2 quarters · filed 2015-11-10 | $2.72M 10-Q · filed 2015-11-10 | $4.45M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-06-30 | $2.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $1.23M 10-Q · filed 2015-08-14 | $2.96M derived: sum of 3 quarters · filed 2016-02-26 | $3.82M derived: sum of 4 quarters · filed 2016-02-26 | |
| 2014-03-31 | -$1.19M 10-Q · filed 2015-05-12 | $545.00K derived: sum of 2 quarters · filed 2016-02-26 | $1.40M derived: sum of 3 quarters · filed 2016-02-26 | $1.57M derived: sum of 4 quarters · filed 2016-02-26 | $3.50M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $1.73M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $2.59M derived: sum of 2 quarters · filed 2016-02-26 | $2.76M derived: sum of 3 quarters · filed 2016-02-26 | $2.43M 10-K · filed 2016-02-26 | |
| 2013-09-30 | $859.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $1.03M derived: sum of 2 quarters · filed 2014-11-10 | $695.00K 10-Q · filed 2014-11-10 | ||
| 2013-06-30 | $168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$164.00K 10-Q · filed 2014-08-11 | |||
| 2013-03-31 | -$332.00K 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |